Tessera Therapeutics
Melanie Chen is a highly experienced researcher in the field of biotechnology and pharmacology, currently serving as a Senior Research Associate at Tessera Therapeutics since November 2021, following a role as Research Associate II. Prior to this position, Melanie worked at Dyno Therapeutics as a Research Associate I focused on in-vitro analysis and AAV engineering. Earlier experiences include analyst and research associate roles at Sartorius Stedim Biotech, where responsibilities encompassed biosafety testing and GxP compliance, as well as managerial tasks at Boston University School of Medicine, which included administrative oversight and behavioral assay execution. Melanie's academic background includes a Bachelor of Science in Neurobiology, Physiology, and Behavior from the University of California, Davis, complemented by practical research roles that investigated neural mechanisms and genetic factors related to addiction and pain.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.